Landsteiner has restructured its debt and received an equity injection from BID Group
June 2023 — Landsteiner Scientific has completed the successful restructuring of US$190 million of debt under Chapter 11 and has received an equity injection of US$ 20 million from BID Group.
Founded in 1998, Landsteiner is a Mexican pharmaceutical company leader on the development, manufacture and distribution of generic and biotechnological healthcare products. The company operates two state-of-the-art pharmaceutical plants. Landsteiner has over 100 registered molecules from 16 different therapeutic areas and has over 200 different product presentations.
BID Group is an investment fund founded in Mexico City. The group consists of seven business units successfully built over the past 25 years: payroll loan, financial services, IT projects, energy/power supply, construction and operation of infrastructures, venture capital and medical supply solutions.
Our role in the transaction
Oaklins’ team in Mexico acted as the financial advisor to Landsteiner Scientific in the debt restructuring as well as in the structuring of the stock acquisition by BID Group.
Prata med transaktionsteamet
Relaterade transaktioner
Cibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Lär dig merKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Lär dig merGroGlass has been acquired by Apogee Enterprises
Apogee Enterprises, Inc. (Nasdaq: APOG), a leading US provider of architectural building products, services and high-performance coated materials, has acquired GroGlass, a Latvia-based developer and manufacturer of high-performance anti-reflective and UV-protective glass coatings. The acquisition brings GroGlass’ differentiated coating technologies and materials science expertise into Apogee’s performance surfaces segment, broadening its product offering and market reach while expanding its manufacturing and R&D presence in Europe.
Lär dig mer